Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Consolidated Net Income (2020 - 2026)

Maxcyte has reported Consolidated Net Income over the past 6 years, most recently at -$9.6 million for Q4 2025.

  • Quarterly Consolidated Net Income rose 9.45% to -$9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$44.6 million through Dec 2025, down 8.71% year-over-year, with the annual reading at -$44.6 million for FY2025, 8.71% down from the prior year.
  • Consolidated Net Income was -$9.6 million for Q4 2025 at Maxcyte, up from -$12.4 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $9.3 million in Q4 2021 and troughed at -$12.4 million in Q3 2025.
  • The 5-year median for Consolidated Net Income is -$9.5 million (2024), against an average of -$7.6 million.
  • Year-over-year, Consolidated Net Income skyrocketed 57.12% in 2021 and then crashed 167.55% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at $9.3 million in 2021, then tumbled by 151.68% to -$4.8 million in 2022, then dropped by 9.74% to -$5.3 million in 2023, then crashed by 100.78% to -$10.6 million in 2024, then increased by 9.45% to -$9.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Consolidated Net Income are -$9.6 million (Q4 2025), -$12.4 million (Q3 2025), and -$12.4 million (Q2 2025).